Unicycive Therapeutics Inc. (UNCY)
NASDAQ: UNCYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
UNCY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $97.77M
- Forward P/E
- 4.86
- EPS (TTM)
- -$1.64
- Dividend yield
- None
- 52-week range
- 3.33 – 8.74
- Day range
- 3.35 – 3.62
- Volume / Avg
- 1.36M / 963.80K
- Beta
- —
- Shares outstanding
- 29.18M
52-week range
UNCY stock today
Shares of Unicycive Therapeutics (UNCY) finished lower on Nov 20 at $3.35, a drop of 5.10% or $0.18 per share, versus the S&P 500's 3.70% decline. Shares are 61.7% below their 52-week high of $8.74, set on May 14, 2026 and 0.6% above the 52-week low of $3.33, near the bottom of the past year's range. UNCY is down 41.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.0%.
Unicycive Therapeutics has posted a net loss over the last twelve months (EPS of -$1.64), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Unicycive Therapeutics
Company profileUnicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Shalabh K. Gupta M.D., MPA
- Headquarters
- Mountain View, CA
- Employees
- 21
- IPO year
- 2021
- Website
- unicycive.com
Financial highlights
Full financialsUnicycive Therapeutics reported a net loss of $26.6 million, compared with a loss of $36.7 million a year earlier. Diluted earnings per share came in at -$1.67.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $675.00K | $951.00K | — |
| Growth | — | — | -29.02% | — | — |
| Net income | $-26.55M | $-36.73M | $-30.54M | $-18.06M | $-10.02M |
| EPS (diluted) | $-1.67 | $-5.65 | $-1.28 | $-1.20 | $-0.86 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$26.30+685.07%
- Strong buy 2
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.25 vs $-0.33
- Surprise
- +24.24%
UNCY news
All UNCY news- Unicycive Therapeutics Announces FDA Acceptance of OLC NDA Resubmission and Third Quarter 2026 Financial ResultsNasdaqUNCY, CFR
- Unicycive's OLC Resubmission Clears FDA Filing Review; Decision Due March 2027; Stock UpNasdaqUNCY, LEN.B
- Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswire
- Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitPR Newswire
- Average Analyst Price Target for Unicycive Therapeutics Rises 12.32% to $32.54Nasdaq
- Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action LawsuitPR Newswire
- Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027GlobeNewswire
Unicycive Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CNTNCanton Strategic Holdings Inc. | 1.21 | -1.63% | $98.78M | vs UNCY |
| NBPNovaBridge Biosciences ADR | 0.83 | -5.66% | $96.28M | vs UNCY |
| NERVMinerva Neurosciences Inc | 2.00 | -5.66% | $99.67M | vs UNCY |
| PDSBPDS Biotechnology Corporation | 0.7774 | -3.70% | $95.39M | vs UNCY |
| ORGOOrganogenesis Holdings Inc. Class A | 0.7716 | -2.23% | $100.16M | vs UNCY |
| NRXPNRX Pharmaceuticals Inc. | 2.15 | -15.69% | $95.31M | vs UNCY |
| DERMJourney Medical Corporation | 3.30 | -7.04% | $93.16M | vs UNCY |
| CLLSCellectis S.A. ADR | 0.9209 | -7.89% | $92.76M | vs UNCY |
Indexes, lists and sector
Unicycive Therapeutics stock FAQ
What is Unicycive Therapeutics's stock price today?
UNCY last traded at $3.35 as of Nov 20, 4:00 PM EST, down 5.10% on the day. Prices are delayed at least 15 minutes.
Does Unicycive Therapeutics pay a dividend?
No. Unicycive Therapeutics does not currently pay a regular cash dividend.
Who is Unicycive Therapeutics's CEO?
Dr. Shalabh K. Gupta M.D., MPA is the chief executive officer of Unicycive Therapeutics Inc., which has about 21 employees.
Has UNCY ever split its stock?
Yes. The most recent UNCY stock split was a 1-for-10 split on Jun 20, 2025.
What is the UNCY 52-week high?
The 52-week high for UNCY is $8.74 and the 52-week low is $3.33. The stock is currently 61.7% below its high.